Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Virtual workouts tested to boost fitness in metastatic breast cancer

NCT ID NCT05468034

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a 16-week virtual exercise program can improve fitness, muscle strength, and quality of life in people with indolent (slow-growing) metastatic breast cancer. Participants work with a trainer three times a week via video calls. The goal is to see if exercise can help people feel better and stay stronger, even with advanced cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
supervised virtual exercise training (aerobic and resistance)
What this could lead to
If it works, this could show that regular virtual exercise helps people with stable metastatic breast cancer feel better, move better, and maintain muscle.
What could go wrong
This is a small, early-stage study with only 100 participants. Exercise may not improve outcomes for everyone, and results may not apply to those on chemotherapy or with progressive disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years 2. Diagnosis of metastatic breast cancer 3. No progression of disease in the 12 months prior to screening per the treating investigator 1. If participant has changed treatments in the prior 12 months for reasons other than progressive disease, they remain eligible 2. Participants on no treatment or "no evidence of disease" but still with a diagnosis of metastatic breast cancer are eligible 4. ECOG performance status of 0-2 5. Ability to walk on a treadmill without assistive device. 6. Informed consent and authorization of the release of health information must be obtained according to institutional guidelines 7. Currently not meeting physical activity guidelines (defined as less than 150 minutes of moderate to vigorous exercise per week measured by the IPAQ questionnaire administered during screening) 8. Participants should have a cellular device compatible with iOS 15 or Android operating system 7. Exclusion Criteria: 1. Receiving cytotoxic chemotherapy at any point in the prior 12 months. 1. Participants receiving endocrine therapy are eligible. 2. Participants receiving targeted therapy or antibody therapy are eligible (examples including trastuzumab, pertuzumab, TDM-1, trastuzumab deruxtecan, sacituzumab govetecan, immunotherapy, CDK4/6 inhibitors, olaparib, alpelisib, etc.) 2. Any condition precluding supervised exercise participation. A letter from a physician supporting participation can supersede this eligibility criteria. * NYHA class III or IV congestive heart failure * Uncontrolled angina * Myocardial infarction in the prior 12 months * Orthopedic surgery in the previous 3 months or plans for orthopedic surgery during the study period * Chronic uncontrolled pulmonary conditions such as uncontrolled asthma (symptoms \> 2 days/week) or dyspnea requiring oxygen * Symptomatic peripheral vascular disease * Or any other comorbidity that would interfere with the ability to complete and comply with the protocol in the opinion of the investigator, including psychological illness * History of fragility fracture 3. Active, untreated brain metastases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • IU Health Joe and Shelly Schwarz Cancer Center

    WITHDRAWN

    Carmel, Indiana, 46032, United States

  • IU Health West

    WITHDRAWN

    Avon, Indiana, 46123, United States

  • Indiana University Melvin & Bren Simon Cancer Center

    RECRUITING

    Indianapolis, Indiana, 46202, United States

  • Sidney and Lois Eskenazi Hospital

    WITHDRAWN

    Indianapolis, Indiana, 46202, United States

  • Yale Cancer Center

    COMPLETED

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.